Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
31 hedge funds and large institutions have $70.9M invested in Astria Therapeutics in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.
87% more capital invested
Capital invested by funds: $37.9M → $70.9M (+$33M)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
15% more funds holding
Funds holding: 27 → 31 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.89% less ownership
Funds ownership: 66.58% → 61.69% (-4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.51M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.1M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$866K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$811K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.08M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$432K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$79K |
| 4 |
D.E. Shaw & Co
New York
|
-$52K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$52K |
ATXS Hedge Fund Activity: Q3 2016 in Review
31 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2016, worth a combined $70.9M — up 87% from $37.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ATXS positions and 6 closed out — a net gain of 4 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $3.51M. The largest seller was Rhenman & Partners Asset Management, cutting an estimated $1.08M.
- 31 institutional investors held Astria Therapeutics (ATXS) as of Q3 2016, up from 27 in Q2 2016.
- Funds reported $70.9M of Astria Therapeutics stock for Q3 2016, up 87% quarter-over-quarter.
- 10 funds opened new Astria Therapeutics positions in Q3 2016 and 6 closed out, a net change of +4 holders.
- The largest Astria Therapeutics buyer in Q3 2016 was Cormorant Asset Management, an estimated $3.51M added.
- The largest Astria Therapeutics seller in Q3 2016 was Rhenman & Partners Asset Management, an estimated $1.08M sold.
Based on aggregated 13F filings for Q3 2016.